Editorial

Sonja von Aulock

Guidelines for FAIR sharing of preclinical safety and off-target pharmacology data

Katharine Briggs, Nicolas Bosc, Tima Camara, Carlos Diaz, Phil Drew, William C. Drewe, Jan Kors, Erik van Mulligen, Manuel Pastor, Francois Pognan, Jordi Ramon Quintana, Sirarat Sarntivijai, Thomas Steger-Hartmann

Associations between clinical signs and pathological findings in toxicity testing

Antero V. Silva, Ulf Norinder, Elin Liiv, Björn Platzack, Mattias Öberg, Elin Törnqvist

TBBPA targets converging key events of human oligodendrocyte development resulting in two novel AOPs

Jördis Klose, Julia Tigges, Stefan Masjosthusmann, Katharina Schmuck, Farina Bendt, Ulrike Hübenthal, Patrick Petzsch, Karl Köhrer, Katharina Koch, Ellen Fritsche

Driver mutations in major lung cancer oncogenes can be analyzed in Drosophila models

Judith Bossen, Karin Uliczka, Line Steen, Pia Neugebauer, Mandy Mong-Quyen Mai, Christine Fink, Frank Stracke, Holger Heine, Thomas Roeder

Galleria mellonella as an alternative in vivo model to study bacterial biofilms on stainless steel and titanium implants

Gopala K. Mannala, Markus Rupp, Francisca Alagboso, Maximilian Kerschbaum, Christian Pfeifer, Ursula Sommer, Marian Kampschulte, Eugen Domann, Volker Alt

Modular micro-physiological human tumor/tissue models based on decellularized tissue for improved preclinical testing

Johanna Kühnemundt, Heidi Leifeld, Florian Scherg, Matthias Schmitt, Lena C. Nelke, Tina Schmitt, Florentin Baur, Claudia Göttlich, Maximilian Fuchs, Meik Kunz, Matthias Peindl, Caroline Brähler, Corinna Kronenthaler, Jörg Wischhusen, Martina Prelog, Heike Walles, Thomas Dandekar, Gudrun Dandekar, Sarah L. Nietzer

Performance of monocyte activation test supplemented with human serum compared to fetal bovine serum

Marijke W. A. Molenaar-de Backer, Eelo Gitz, Miranda Dieker, Paulien Doodeman, Anja ten Brinke

How a GIVIMP certification program can increase confidence in in vitro methods

Amanda Ulrey, Susanne Kolle, Robert Landsiedel, Erin Hill

Mind the gaps: Prioritizing activities to meet regulatory needs for acute systemic lethality

Kristie M. Sullivan, David G. Allen, Amy J. Clippinger, Daniel M. Wilson, Stephen W. Edwards, Kyle Glover, Kamel Mansouri, Raja Settivari, Sanjeeva J. Wijeyesakere, Warren Casey

Applying evidence-based methods to the development and use of adverse outcome pathways

Rob B. M. de Vries, Michelle Angrish, Patience Browne, Jan Brozek, Andrew A. Rooney, Daniele S. Wikoff, Paul Whaley, Stephen W. Edwards, Rebecca L. Morgan, Ingrid L. Druwe, Sebastian Hoffmann, Thomas Hartung, Kristina Thayer, Marc T. Avey, Brandiese E. J. Beverly, Maicon Falavigna, Catherine Gibbons, Katy Goyak, Andrew Kraft, Fernando Nampo, Amir Qaseem, Meg Sears, Jasvinder A. Singh, Catherine Willett, Erin Y. Yost, Holger Schünemann, Katya Tsaioun

Application of computational methods in replacement – an IPAM webinar

Stefano Lorenzetti, Chiara L. Battistelli, Cecilia Bossa, Pietro Cozzini, Alessandro Giuliani, Orazio Nicolotti, Olga Tcheremenskaia, Maurilio Calleri, Francesca Caloni, Cristina M. Failla, Paola Granata, Michela Kuan, Francesco Nevelli, Augusto Vitale, Isabella De Angelis

Understanding COVID-19 through adverse outcome pathways – 2nd CIAO AOP Design Workshop

Clemens Wittwehr, Maria João Amorim, Laure-Alix Clerbaux, Catharine Krebs, Brigitte Landesmann, Donna S. Macmillan, Penny Nymark, Rebecca Ram, Natàlia Garcia-Reyero, Magdalini Sachana, Kristie Sullivan, Jukka Sund, Catharine Willett

Corners

Sonja von Aulock

Characteristics to consider when selecting a positive control material for an in vitro assay

Elijah J. Petersen, Andrew Nguyen, Jeffrey Brown, John T. Elliott, Amy J. Clippinger, John Gordon, Nicole Kleinstreuer, Matthias Roesslein

Imprint

Sonja von Aulock

Advertisement

Sonja von Aulock

Cover

Sonja von Aulock